The USPTO has declined to sign off on an inter partes review of Celgene’s (CELG +2.1%) U.S. Patent No. 8,404,717 covering top seller Revlimid, requested by would-be generic competitor Dr. Reddy’s Laboratories (RDY -5.1%).
The USPTO will decide on two additional patents, No. 9,056,120 and No. 7,189,740, any day.